Neisseria meningitidis capsular polysaccharide antigens (CPS)

Neisseria meningitidis capsular polysaccharide antigens are critical virulence factors that form the outermost protective layer of the bacterium, shielding it from host immune mechanisms such as opsonophagocytosis and complement-mediated lysis (PubMed: 22412090). These polysaccharides are composed of repeating carbohydrate units whose chemical structures define the various serogroups, most notably A, B, C, W-135, and Y (CDC: Meningococcal Disease). In clinical medicine, these antigens serve as the primary components of meningococcal vaccines designed to prevent invasive disease, including life-threatening meningitis and septicemia. While pure polysaccharide vaccines elicit T-cell independent immune responses, conjugate vaccines link these sugars to carrier proteins to induce a robust T-cell dependent memory response, which is particularly effective in infants and young children (StatPearls: Meningococcal Vaccine). Notably, the serogroup B polysaccharide is generally excluded from these vaccines because its structure mimics human neural cell adhesion molecules, leading to poor immunogenicity and theoretical risks of autoimmunity (WHO: Meningococcal meningitis). Consequently, targeting these polysaccharides through vaccination remains a cornerstone of public health strategies to control meningococcal outbreaks and endemic disease.

Other names

Meningococcal capsular polysaccharidesMenCPSBacterial capsular polysaccharidesSerogroup-specific polysaccharides

Vaccines targeting these antigens induce the production of serogroup-specific bactericidal antibodies. These antibodies bind to the capsular polysaccharides on the bacterial surface, which activates the classical complement pathway and facilitates opsonophagocytosis by host leukocytes (PubMed: 11553240). Conjugate vaccines improve this process by linking the polysaccharide to a carrier protein, thereby recruiting T-helper cells to produce high-affinity antibodies and long-term immunological memory (CDC: Vaccine Principles).